This document discusses manufacturing considerations for ophthalmic dosage forms. It begins by defining ophthalmic preparations and listing their key requirements like sterility, tonicity, and avoidance of particulates. It then covers the manufacturing environment, personnel requirements, equipment needs, raw materials, and process analytical technology (PAT). Specific manufacturing operations for ophthalmic preparations in glass and plastic containers are outlined, including areas, equipment, and processing steps for water management, container preparation, solution preparation, filling/capping, sterilization, inspection, and packaging. Common ophthalmic dosage forms and their advantages and disadvantages are also briefly mentioned.
University Institute of Pharmaceutical Sciences is a flag bearer of excellence in Pharmaceutical education and research in the country. Here is another initiative to make study material available to everyone worldwide. Based on the new PCI guidelines and syllabus here we have a presentation dealing with "Aseptic requirements for parenteral products".
Thank you for reading.
Hope it was of help to you.
UIPS,PU team
Aseptic Area and Microbial Control. - Pharmaceutical Microbiology (SYBpharm) ...Kiran Shinde
Prof.Mr.Kiran K. Shinde (M.Pharm), Assistant professor (VNIPRC)
Pharmaceutical microbiology (Second year b.pharm) (3rd semester)
Introduction to Aseptic area & room
Designing of Aseptic Room
Laminar Airflow Equipment
Sources of Contamination & Method of Prevention
Classification of Aseptic Area-Room
Testing of Clean Aseptic Room
Designing of aseptic area, laminar flow equipment: Study of different source ...Ms. Pooja Bhandare
Designing of aseptic area, laminar flow equipment: Study of different source of contamination in aseptic area and methods of prevention, clean area classification. PHARMACEUTICALMICROBIOLOGY (BP303T)Unit-IVPart-1
Introduction: Designing of Aseptic Area . i) The clean-up area,
ii) The compounding area,
iii) The aseptic area,
iv) The quarantine area and
v) The packaging/labelling area.
Flow diagram of aseptic area. Floors, walls and ceilings, Doors, windows and services Personnel and protective clothing Cleaning and disinfection. Air Supply. Laminar flow equipment. Vertical laminar air flow bench
Horizontal laminar air flow bench
High Efficiency Particulate Air (HEPA) Filter. Operating Instructions Uses of Laminar Air Flow.Advantages of Laminar Air Flow.Limitations of Laminar Air Flow. Air flow pattern Unidirectional airflow
Non-unidirectional airflow
Combined airflow
Different Sources of Contamination in an Aseptic Area
1) Personnel:
2) Buildings and Facilities
3) Equipment and Utensils:
4) Raw Materials
5) Manufacturing Process:
Methods of Prevention of Contamination Clean Area Classification
University Institute of Pharmaceutical Sciences is a flag bearer of excellence in Pharmaceutical education and research in the country. Here is another initiative to make study material available to everyone worldwide. Based on the new PCI guidelines and syllabus here we have a presentation dealing with "Aseptic requirements for parenteral products".
Thank you for reading.
Hope it was of help to you.
UIPS,PU team
Aseptic Area and Microbial Control. - Pharmaceutical Microbiology (SYBpharm) ...Kiran Shinde
Prof.Mr.Kiran K. Shinde (M.Pharm), Assistant professor (VNIPRC)
Pharmaceutical microbiology (Second year b.pharm) (3rd semester)
Introduction to Aseptic area & room
Designing of Aseptic Room
Laminar Airflow Equipment
Sources of Contamination & Method of Prevention
Classification of Aseptic Area-Room
Testing of Clean Aseptic Room
Designing of aseptic area, laminar flow equipment: Study of different source ...Ms. Pooja Bhandare
Designing of aseptic area, laminar flow equipment: Study of different source of contamination in aseptic area and methods of prevention, clean area classification. PHARMACEUTICALMICROBIOLOGY (BP303T)Unit-IVPart-1
Introduction: Designing of Aseptic Area . i) The clean-up area,
ii) The compounding area,
iii) The aseptic area,
iv) The quarantine area and
v) The packaging/labelling area.
Flow diagram of aseptic area. Floors, walls and ceilings, Doors, windows and services Personnel and protective clothing Cleaning and disinfection. Air Supply. Laminar flow equipment. Vertical laminar air flow bench
Horizontal laminar air flow bench
High Efficiency Particulate Air (HEPA) Filter. Operating Instructions Uses of Laminar Air Flow.Advantages of Laminar Air Flow.Limitations of Laminar Air Flow. Air flow pattern Unidirectional airflow
Non-unidirectional airflow
Combined airflow
Different Sources of Contamination in an Aseptic Area
1) Personnel:
2) Buildings and Facilities
3) Equipment and Utensils:
4) Raw Materials
5) Manufacturing Process:
Methods of Prevention of Contamination Clean Area Classification
This session from the Institute of Validation Technology's Contamination and Control Week discusses regulatory expectations and industry drivers for aseptic cleaning and environmental monitoring, regulatory expectations for cleanrooms, and current FDA and EU expectations during inspection of sterile and aseptic operations.
This presentation contains general guidelines and basic requirements of manufacturing of sterile medicinal products. This presentation is useful for training to the people involved in manufacturing of sterile pharmaceuticals or medicines.
Aseptic / sterile - “ A state of control attained by using an aseptic work area and performing activities in a manner that precludes microbiological contamination of the exposed sterile product”
Validation of aseptic process should be designed to provide assurance through appropriate testing that all phases and activities of the process remain sterile and it is controlled within the predetermined parameters.
Drug product, container, and closure are subject to sterilization separately, and then brought together.
MANUFACTURING OF PARENTRALS
1. Formulation and Raw Materials:
Concept: The process begins with the formulation of the parenteral drug, determining its composition and concentration.
Raw Materials: High-quality pharmaceutical-grade raw materials, including active pharmaceutical ingredients (APIs), excipients, and solvents, are selected based on their compatibility and purity.
2. Sterilization of Raw Materials:
Concept: Due to the sterile nature of parenteral products, all raw materials, including the API and excipients, must undergo rigorous sterilization.
Methods: Common sterilization methods include autoclaving, filtration, and aseptic processing to ensure aseptic conditions throughout the manufacturing process.
3. Manufacturing Process:
Preparation: The formulation is prepared, and various components are weighed and measured precisely.
Mixing: The ingredients are mixed under controlled conditions to achieve a homogeneous blend, ensuring uniform distribution of the API and other components.
Filtration: The solution is then filtered to remove any particulate matter and ensure clarity.
Filling: The sterile drug solution is filled into vials, ampoules, or other suitable containers in a controlled environment, maintaining sterility.
4. Sterilization of Final Product:
Terminal Sterilization: The final product, in its container, undergoes terminal sterilization methods like autoclaving or gamma irradiation to eliminate any microbial contamination that may have occurred during the manufacturing process.
Aseptic process tech & advanced sterile product mfg rashmi nasareRASHMINasare
Aseptic process technology & advanced sterile product manufacturing technology it is done for doing in process quality control test for sterile product
This session from the Institute of Validation Technology's Contamination and Control Week discusses regulatory expectations and industry drivers for aseptic cleaning and environmental monitoring, regulatory expectations for cleanrooms, and current FDA and EU expectations during inspection of sterile and aseptic operations.
This presentation contains general guidelines and basic requirements of manufacturing of sterile medicinal products. This presentation is useful for training to the people involved in manufacturing of sterile pharmaceuticals or medicines.
Aseptic / sterile - “ A state of control attained by using an aseptic work area and performing activities in a manner that precludes microbiological contamination of the exposed sterile product”
Validation of aseptic process should be designed to provide assurance through appropriate testing that all phases and activities of the process remain sterile and it is controlled within the predetermined parameters.
Drug product, container, and closure are subject to sterilization separately, and then brought together.
MANUFACTURING OF PARENTRALS
1. Formulation and Raw Materials:
Concept: The process begins with the formulation of the parenteral drug, determining its composition and concentration.
Raw Materials: High-quality pharmaceutical-grade raw materials, including active pharmaceutical ingredients (APIs), excipients, and solvents, are selected based on their compatibility and purity.
2. Sterilization of Raw Materials:
Concept: Due to the sterile nature of parenteral products, all raw materials, including the API and excipients, must undergo rigorous sterilization.
Methods: Common sterilization methods include autoclaving, filtration, and aseptic processing to ensure aseptic conditions throughout the manufacturing process.
3. Manufacturing Process:
Preparation: The formulation is prepared, and various components are weighed and measured precisely.
Mixing: The ingredients are mixed under controlled conditions to achieve a homogeneous blend, ensuring uniform distribution of the API and other components.
Filtration: The solution is then filtered to remove any particulate matter and ensure clarity.
Filling: The sterile drug solution is filled into vials, ampoules, or other suitable containers in a controlled environment, maintaining sterility.
4. Sterilization of Final Product:
Terminal Sterilization: The final product, in its container, undergoes terminal sterilization methods like autoclaving or gamma irradiation to eliminate any microbial contamination that may have occurred during the manufacturing process.
Aseptic process tech & advanced sterile product mfg rashmi nasareRASHMINasare
Aseptic process technology & advanced sterile product manufacturing technology it is done for doing in process quality control test for sterile product
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
2. CONTENTS ….
1. INTRODUCTION
1 Definition
2 Types of ophthalmic dosage forms
2. MANUFACTURING CONSIDERATION
1 Environment
2 Personnel requirements
3 Equipments
4 Raw material
5 PAT (process analytical technology)
3. MANUFACTURING OPERATION
1 Area requirement
2 Equipments as per schedule M
3 Process flow chart
4 Simpler flow diagram showing arrangement of different area
5 Manufacturing operation of ophthalmic preparations
6 Packaging
4. OPHTHALMIC PREPARATION CHARACTERISTICS
5. QUALITY CONTROL TESTS
6. DOCUMENTATION
7. REFERENCES
3. 1. INTRODUCTION
1. DEFINITION:
“ophthalmic preparation are sterile
Product that are intended to be applied to the eyelids or placed
in the space between the eyelids and the eyeball.
Ophthalmic preparation are similar to parenteral dosage
forms in their requirement for:
1.Sterility
2.Tonicity (osmotic pressure)
3.Preservation
4.Tissue compatibility
5.Particulate matter
6.Avoidance of pyrogens (not as critical as other parenteral
products)
7.Suitable packaging
4. DOSAGE FORMS ADVANTAGES DISADVANTAGES
1. Solutions -convenience -rapid corneal elimination.
-loss of drug by drainage.
No sustained action
2. Suspensions -patient compliance
-best of drug with slow dissolution
-drug properties decide performance.
-loss of both solution & suspended
solid.
3. Emulsions -prolonged release of drug from
vehicle.
-enhanced pulsed entry.
-patient non compliance.
-Blurred vision
-possible oil entrapment.
4. Ointments -Flexibility in drug choice
-improved drug stability
-increased tissue contact time.
-inhibition of dilution by tears.
-sticking of eyelids.
-poor patient compliance
-blurred vision
-no true sustained effect.
5. Gels -comfortable
-less blurred vision than ointment.
-no rate control on diffusion.
-matted eyelids after use.
6.Erodible inserts -effective
-flexiblility in drug type & dissolution
rate
-need only be introduced into eye & not
removed.
--patient discomfort
-requires patient insertion
-occasional product.
7. Non-erodible inserts -controlled rate of release
-prolonged delivery
-flexibility for type of drug selected.
-sustained release
-patient discomfort
-irritation to eye
-tissue fibrosis
TYPES/CLASSES OF OPHTHALMIC DOSAGE FORMS :
5. 2. Manufacturing considerations in design of
ophthalmic production facility:
Because the official compendia require all topically
administered ophthalmic medication to be sterile, the manufacturer
of such medication must consider all the current concepts in the
manufacture of sterile pharmaceuticals in designing a manufacturing
procedure for sterile ophthalmic pharmaceutical products.
The manufacture of sterile ophthalmic pharmaceutical products
requires special attention to:
1. Environment 2. Personnel Requirements
3. Equipments 4. Raw Material
5. PAT (Process Analytical Technology)
6. 1 ENVIRONMENT:
Current U.S. std. for GMP provide for the use of specially
designed environmentally controlled areas for the manufacturing
of sterile large & small volume injections and ophthalmic for
terminal sterilization.
Grade Types of Operations for Terminally Sterilized Products
A Filling of products
C Placement of filling and sealing machines,
preparation of solutions
D blowing (pre-forming) operations of plastic
containers & closers.
7. Grade Types of Operations for Aseptic Preparations
A Aseptic preparation and filling
B Background room conditions for activities
requiring Grade A
C Preparation of Solution to be filtered
D Handling of components after washing
Note :
Grade A and B correspond to with class 100
Grade C correspond to with class 10000
Grade D correspond to with class 100000
(Class 100 : NMT 100 particles /ft3 of air of diameter of 0.5 µm or
larger)
8. • Class 10,000: area contains NMT 10,000 particles of
0.5 microns and even larger per cubic feet of air
• The areas where the containers and closures are
not exposed to the environment and in which the
processes of filling and capping are not undertaken
• Can be achieved by conventional air conditioning.
9. • Class 100:
• Area contains NMT 100 particles of 0.5 microns and
larger per cubic feet of air.
• areas where the containers and closures are
exposed to the environment and areas associated
with filling and capping processes are required to
meet the requirements of class 100.
• This class 100 condition can be achieved by laminar
air flow.
10. Monitoring and evaluation of production
environment
• Particle count: Number of particles in as ample of
air by particle measuring systems – measures only
dust particles not viable forms.
• Slit to agar sampler
• Rodac plates- consists of nutrient agar with convex
surface .
• The plate is rolled on the surface to be tested where
MO sticks to the surface of agar plate
• Plates are incubated during which MO starts
growing
11. a)Walls,ceiling&floors
Constructed of material →hard, non flaking , smooth &
unaffected by surface cleaning agents & disinfectants.
For that epoxy or vinyl ceiling coat for finishing avoids holes on
surface.
b)Alllights&windows
Should be flush mounted in walls & ceilings for ease of
cleaning&disinfection
c)U.V.lamps
May be provided in recessed , flush mounted fixtures to
maintainsurfacedisinfection
d)Separateentrance
For both personnel & equipments (specially designed air
locks maintained at negative pressure relative to aseptic
manufacturing area & at positive pressure relative to non-
environmentally controlled area.
12. 2 PERSONNEL REQUIREMENTS
Physically fit
No. of workers should kept to a minimum- to
minimize human derived particulate matter which
includes the epidermal cells, hair.
Training of personal
Sterile uniform
Personal hygiene:-
All employees should be in good health,
Subjected to Physical examination,
Understood their responsibilities to report
own illness like cold, a sore throat, or
other infection.
• conditions maintained in the working area. RH – 40
to 60 % and temp between 20-250c
13. Traffic control
• Traffic includes
• Supply of materials
• Entry and exit of the workers in the production area
• Traffic should be strictly controlled in aseptic rooms
• Prescribed procedure should be followed for every
person who enters aseptic areas
• They should change their clothes, cover their faces with
masks, wear hand gloves, head covers or caps and
shoes
• Once a person enters the aseptic area, he or she cannot
leave until completion of MFG cycle
• Entry of unauthorized persons in this area should be
restricted
14. General cleaning
• Cleaning schedule should be developed and
followed on a daily or monthly basis based on
sterility requirements .
• General cleaning and surface disinfection
• Sanitization is carried out using disinfectants or UV
radiation before starting the production
• Cleaning and sanitization carried out in two ways
• A. By spraying a suitable liquid disinfectant over all
the surfaces in aseptic areas/ by wiping surfaces
with liquid disinfectant
15. • Surface disinfection is achieved by use of germicidal
UV lamps
• Irradiation of UV light rays is done to decrease the
population of bacteria in aseptic areas.
• Direct irradiation is carried out only when the room
is vacant.
16. Cleaning of air
• Greatest source of contamination is air entering
aseptic area as air contains most of the bacteria
• Conventional systems/ class 10,000
• Consists of two air conditioners fixed at ceiling and
at the bench level respectively
• This area is responsible for the control of dust
particles, humidity and temperature
• Before entering the air is dehumidified, cooled and
filtered
• This filtered air is allowed to enter at a velocity of
800ft/min
17. • Laminar flow systems
• Used for cleaning air in aseptic rooms
• To remove bacteria/ dust particles
• Clean air obtained by use of HEPA filters
18. 3 EQUIPMENTS :
sterile – because of direct contact with the ingredients
during formulation
All tanks , valves , pipings →best available grade of corrosion-
resistant stainless steel.(S.S. type 304 or 316) is preferable.
All the product contact surface should be finished either
mechanically or by electro polishing to provide a surface as free as
possible from scratches or defects.
For the equipment that will reside in aseptic filling areas such as
filling & capping machine, care should be taken in their design to
yield equipment as free as possible from particle generating
mechanisms.
19. • Advancement in technology – specialized
equipments that can be cleaned in their positions
itself – clean – in – place concept.
• CIP and SIP equipments
• Sequence of treatments for CIP systems
• Chlorinated water rinse filtered air blow->
detergent wash-> filtered air blow-> Chlorinated
water rinse-> filtered air blow-> WFI rinse-> filtered
air blow.
20. • Sterilization of equipments :
• Materials which can with stand high temps
rendered sterile by dry heat sterilization at a temp
of 170 c or above for an hour/ 140 c for 3 hrs.
• Which cannot with stand high temps sterilized by
moist heat sterilization by use of autoclave at 121 c
15 psig for 20 mins / 130 c 27 psig for 3 mins
• Before MHS equipment thoroughly rinsed with 80c
pyrogen free water.
21. • Equipments which are sensitive to autoclaving
temps gas sterilization by ethylene oxide.
• Equipments which are exclusively employed in the
sterile area such as bottles, filling machinery,
sterilizing membranes, stoppering equipment,
tanks, utensils, vent filters must be sterilized just
before sterile operation.
22. 4 RAW MATERIAL :
Highest quality, sterile
Specifications laid down by regulatory authorities strictly
followed
Care on particle size. Eye sensitive to particle size >25 microns
23. In most sterile dosage form largest proportion is of
“water” which is main source of contamination.
For the preparation intended for parenteral
administration ,U.S.P. xxii requires the use of
→ WFI
→ SWFI
→ BWFI
All of above are produced by distillation or reverse
osmosis & kept in circulation at relatively high
temperature up to 800c, or alternatively its disposal
at every 24 hrs, in all S.S. equipment of highest
attainable , corrosion resistant quality
24. 5 PAT (PROCESS ANALYTICAL TECHNOLOGY)
The product manufacturing & quality control is
governed by the c GMP regulation.
For better output ,PAT is to be followed.
“System for designing ,analyzing &
controlling manufacturing through timely
measurements (during process) of critical quality
& performance attribute of raw & in process
material & process with a goal of ensuring final
product quality. ”
25. 3. MANUFACTURING OPERATION
A. AREA REQUIREMENT
Minimum of 10 m2 → for ancillary area
Minimum of 25 m2 → for basic installation
Manufacturing & filling shall be carried out in air –conditioned areas
under aseptic condition
The rooms shall be further dehumidified as considered necessary if
preparation containing antibiotics are manufactured.
26. B. LIST OF EQUIPMETNS AS PER
SCHEDULE M
For Ophthalmic solutions & suspensions
1. Jacketed kettle/stainless steel tanks(steam gases electrically
heated)
2. Mixing & storage tanks of stainless steel/planetary mixer
3. Sintered glass funnel , Seitz filter or filter candle(preferably
cartridge & membrane filter)
4. Liquid filling equipments (semi automatic & automatic filling
machine)
For Ophthalmic Ointments
1. Colloid mill/ointment mill
2. Tube filling & crimping equipment(semi automatic &
automatic filling machine)
3. Tube cleaning equipments (air jet type)
4. Tube washing & drying equipments
27. EQUIPMETNS
1. Thermostatically controlled Hot air oven. (preferably
double ended)
2. Autoclave (preferably ventilator autoclave)
3. Air conditioning & dehumidification arrangement
4. Laminar air flow units.
5. Automatic vial washing machine
6. Vial drying oven
7. Distillation unit
8. Packaging & labeling
9. Inspection machine
28. Multicolumn distillation unit
It consist of specially designed columns
which make optimum use of the
principles of inter stage heat exchange
(Multi effect distillation method) to
produce pure pyrogen free sterile
distilled water for injectables as per
IP/BP specification.
30. SS Tank with Stirrer / Manufacturing
vessel
• With SS steam jacketed &
insulation with SS cladding.
• Different type of stirrer
(paddle/ anchor/propeller)
available.
• Electric heating also possible
for small scale.
32. Triple roller mill
• It’s used for grinding ointment,
pastes, paints, etc.
• Side scrappers moves up and
down with compression spring
and knob to secure appropriate
working pressure
33. ROTARY TUBE FILLING
MACHINE
• Rotary tube filling &
closing (crimping) machine
with coding device.
• Speed :- 30 to 80 TPM
• Another TWIN HEAD
machine also available in
market.
35. Fully Automatic Labeling Machine SBSL-
120F
• Fully Automatic, User Friendly, Sticker (Self-Adhesive)
Labeling Machine Model SBSL-120F,
• Suitable to apply accurate Labels on Double Side (Front
& Back) of Flat/Oval/Square shaped products .
36. Manual Vial & Bottle Inspection machine
Out put Approx. 80 to 250 vials per
minute
No of
operator
six
37. Automatic Packaging Conveyor
•Conveyor belt is used as a PVC coated canvas belt /
endless rubberized belt.
•The Reduction Gear Box provides jerk less &
noiseless performance for long time.
38. STEAM STERILIZER or AUTOCLAVE
used for sterilizing
• Solutions in glass containers like ampoules,
vials, glass bottles etc.
40. D. FLOW DIAGRAM SHOWING
ARRANGEMENT OF DIFFERENT AREA
OPHTHALMIC– MANUFACTURING PLANT LAYOUT
41. E. MANUFACTURING OPERATION OF
OPHTHALMIC PREPARATIONS
Divided in to two separate areas:-
1. Ophthalmic preparation in glass container.
2. Ophthalmic preparation in plastic container.
42. 1. OPHTHALMIC PREPARATIONS
IN GLASS CONTAINER
Different areas Equipments recommended
Water management area
(water treatment & storage)
1)De-ionised water treatment unit.
2)Distillation (multi column with heat
exchangers) unit.
3)Thermostatically controlled water storage
tank.
4)Stainless steel service lines for carrying
water into user areas.
Container & closure preparation
area
(washing & drying of vials , bottles &
closures)
1)Automatic rotary vial washing machine.
2)Automatic closures washing machine.
3)Storage equipment for vials, bottles and
closures.
4)Dryer / sterilizer (double ended).
5)Dust proof storage cabinets.
43. Different areas Equipments recommended
Solution preparation area
(preparation & filtration of solution)
1) Solution preparation and mixing
2) Stainless steel tanks and other
containers.
3) Portable stirrer.
4) Filtration equipment with
cartridge and membrane filters/
bacteriological filters.
5)Transfer pumps.
6)Stainless steel benches / stools.
Filling, capping and sealing area
(filing , capping , sealing of vials &
bottles)
1)Automatic vial/bottle filling,
sealing and capping machine
under laminar air flow work
station.
2)Gas lines (Nitrogen, Oxygen,
Carbon di-oxide) wherever
required.
3)Stainless steel benches/stools
44. Different areas Equipments recommended
Sterilization area 1)Steam sterilizer (preferably with computer
control for sterilization cycle along with
trolley sets for loading/unloading
containers before and after sterilization).
2)Hot Air sterilizer (preferably double ended).
3)Pressure leak test apparatus.
Quarantine area 1)Storage cabinets.
2)Raised platforms/steel racks
Visual inspection area 1)Visual inspection units (preferably
conveyor belt type and composite white
and black assembly supported with
illumination).
2)Stainless steel benches/stools.
Packaging area 1)Batch coding machine (preferably
automatic).
2)Labeling unit (preferably conveyor belt
type).
3)benches/stools.
45. 2. OPHTHALMIC PREPARATIONS
IN PLASTIC CONTAINER
FORM-FILL-SEAL TECHNOLOGY OR
BLOW-FILL-SEAL TECHNOLOGY
SIMPLE FILL-SEAL TECHNOLOGY
Form-Fill-Seal units are specially built automated
machines in which through one continuous operation,
container's are formed from thermoplastic granules, filled
and then sealed .
Fill-seal units are machines in which containers are
molded (preformed) in separate clean rooms by non
continuous operation then filling & sealing is carried out.
47. PACKAGING
Plastic containers → ease of use
→ little breakage
→ less spoilage
Large volume intraocular solutions of 250ml &500ml
have been packaged in glass, but even this parenteral
type products are beginning to be packaged in specially
fabricated polyethylene/polypropylene containers or
flexible bags.
Type 1 glass vials with appropriate stoppers are used
for intraocular ophthalmic products administered by
injection.
Different ophthalmic cap color coding are given by the
cooperative efforts of FDA , the ophthalmic industry &
academy of ophthalmology .
48. OPHTHALMIC CAP COLOR CODING
Color Pharmaceutical class
Yellow or blue Beta blockers
Gray Non steroidal
Pink Steroidal
Brown Anti infective
Orange Carbonic anhydrase inhibitors
Turquoise Prostaglandins
Red Mydriatics
Green Mitotic
49. 4. Ophthalmic preparation characteristics
1) Clarity:
Ophthalmic solutions by definition contain no
undissolved ingredients & are essentially free from
foreign particles.
But solution containing viscosity imparting polymers
diminish clarity. In these situation it may be important to
define both the visual clarity of the product & monitor its
stability.
The E.P. describes visual clarity & recommended
standards that can be used for clarity specifications.
50. 2) Stability:
The stability of a drug in an ophthalmic product depends
on a number of factors including the chemical nature of the
drug substance, product pH, method of preparation
(particularly temperature exposure), solution additives, &type
of packaging.
Pharmaceutical manufacturers conduct comprehensive
stability programs to assure the assigned expiration dating for
each product.
The stability of the preservative is also monitored by
chemical means or by actual challenge of the preservative
efficacy with appropriate test organisms.
51. 3) Sterility:
The important property of ophthalmic formulations
is that they must be sterile.
The USP-22 listed five methods of achieving sterility.
a) Steam sterilization at 1210c
b) Dry heat sterilization
c) Gas sterilization
d) Sterilization using ionizing radiation
e) Sterilization by filtration
The method chosen is often depends on resistance
of the active ingredient & the resultant product to
heat & to the type of packaging(i.e. container) used.
52. 4) pH adjustment & buffers:
The adjustment of ophthalmic solution pH by the
appropriate choice of a buffer is one of the most
important considerations.
Ideally, ophthalmic preparations should be
formulated at a pH equivalent to the tear fluid value of
7.4
5) Tonicity:
Tonicity refers to the osmotic pressure exerted by
salts in aqueous solution.
An ophthalmic solution is isotonic with another
solution when the magnitudes of the colligative
properties of the solutions are equal.
53. 5. QUALITY CONTROL SPECIFICATION
1) Raw material 2) packing material
- Description - Compatibility
- Moisture content - Stability
- Assay of ingredient
- Purity
3) In process Product
a) Mixing b) Filling
- Assay - weight variation
- Grittiness - content uniformity
- Viscosity
- Density
- pH
54. 4) Product Specification
a) Microbial specification
- limit for total microbial count
- Absence of specific microorganism as per pharmacopoeia
b) Chemical specification
- pH
- Content uniformity
- Chemical potency
c) Physical specification
- clarity
- Particle size
- Density
- Viscosity
55. Compendial requirements for semi-
solid product
• Semi-solid product must meet USP tests for,
1) Microbial content
2) Minimum fill
3) Packing
4) Storage
5) Labeling
• Ophthalmic ointment must meet to the,
- USP sterility tests
- Test for metal particles
• USP directs the ophthalmic ointment must be packed in collapsible tube
with narrow tip.
56. 6. DOCUMENTATION
1. Master formula records
2. Batch formula records
3. Equipment & containers records
4. Filtration & filling records
5. Batch Packaging & Labeling Records
6. IPQC records
57. 1. Master formula records
• Name of the product________________________________________
• Name and Weight of API ____________________________________
• Name and Weight of Ingredient _______________________________
• Description of equipment ____________________________________
• Statement of theoretical yield_________________________________
• Process and packaging procedure_____________________________
• A description of container____________________________________
• closure and packaging material _______________________________
• In process control during processing ___________________________
• In process control during packaging____________________________
• Precaution to be taken______________________________________
58. Environmental control
Product_______________________________ lot no.__________________________
Room________________________________ date exposed_____________________
Media____________________
Date Time Incubation
Temp.
Humidity (in case of
hygroscopic substances)
Plate no Duration Location No. of colonies
59. 2. Batch Manufacturing Records
• Name of the company:-_______________________________________
• Address:-___________________________________________________
• Name of the product _________________________________________
• Active pharmaceutical ingredient ______________________________
• M F R No. __________________________________________________
• Batch No._____________________ Batch size ____________________
• Mfg. date _____________________Date of expiry_________________
• Requisition slip
Sr no Ingredients Item
code
Standards ATR no Label claim Qty
required
Qty
issued
60. 3. Equipment & containers records
• Description of containers _______________________________________
• Q/C report of container ________________________________________
• Date ________________________ Equipment used__________________
• Cleaning agent used ___________________________________________
• Cycle of washing: _____________________________________________
• Sign. Of officer_______________________________________________
If sterilized by dry heat or autoclave:
Articles Date Time when
oven started
Desired
temp.
attained
Temp. Time when
oven switched
off
61. 4. Filtration & filling records
• Equipments used for filtration ___________________________________
• Date__________________________ Time_________________________
• Result of test or analysis of solution_______________________________
• Equipment used for filling_______________________________________
• Date________________________________________________________
• Sign. Of officer_______________________________________________
Time Filling started Filling completed
62. 5.Batch Packaging & Labeling Records
• Product name_______________________ Batch no _______________________
• Strength___________________________ batch size ______________________
• Category___________________________ mfg date _______________________
• MFG no____________________________ exp date _______________________
• Batch Packaging & Labeling Records
• Description of packaging______________________________________________
• Pre-coding of labels & printed packaging materials,
• examined & verified by _______________________________________________
• No. of pre-coded ____________________________________________________
• (ii). Printed packaging material received __________________________________
• Result of bulk finished products ________________________________________
• Sign. Of officer _____________________________________________________
• Reconciliation of labeling and packaging material
• Quantity of material received___________________________________________
• Quantity of material destroyed__________________________________________
• Quantity of material used _____________________________________________
• Quantity of material returned___________________________________________
• Date of release____________________ quantity release____________________
• Signature of supervisor _______________
63. 6. IPQC records
• 1. Visual inspection:
• Description
________________________________________________________
• Total no of filled, sealed & sterilized containers rejected
__________________
• Nature of defects
____________________________________________________
• Name of worker who examined:
(i). ________________________________________________
(ii). _______________________________________________
(ii). _______________________________________________
64. FDA APPROVED DRUGS FOR OPHTHALMOLOGY
* Restasis (Cyclosporine Ophthalmic emulsion):
• In treatment of low tear production.
• * Lumigan(Bimatoplast Ophthalmic Solution): For the reduction of intra
ocular pressure in open-angle glaucoma.
• * Travatan(Travoplast Ophthalmic Solution)
• * Betaxon: For lowering intraocular pressure.
• * Quixin: For bacterial conjuctivitis.
• * Rescula: (Iso propyl) Ophthalmic Solution. In treatment of open-angle
glaucoma.
• * Alamast: Potassium Ophthalmic Solution.
• * ZADITOR:For the prevention of itching of eye.
• * Alrex: For the treatment of allegic conjuctivitis.
• * Cosopit: For the treatment of glaucoma.
65. 7. REFERENCES
• Remington-The science and practice of pharmacy 21st
edition volume I
• 1.Controlled drug delivery by N.K.Jain,
• Page No.(82,85,86,92,94-96)
• 2. Controlled drug delivery by Roop K.Khar & S.P.Vyas,
• Page No.(384-397,399,403)
• Modern pharmaceutics edited by Gilbert S. Banker volume
72
• Pharmaceutical dosage forms parenteral medications
volume 2 edited by Kenneth E. Avis, Leon Lachman
• Pharmaceutical dosage forms Disperse systems volume2
http:// www.optisgroup.com/TechnologyEyegate.htm
• www. Pharmamachine.com